Clinical Trials Logo

CD22 Positive clinical trials

View clinical trials related to CD22 Positive.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03094611 Terminated - Clinical trials for Refractory Acute Lymphoblastic Leukemia

Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia

Start date: November 30, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well inotuzumab ozogamicin works in treating patients with CD22 positive acute lymphoblastic leukemia that has come back or does not respond to treatment. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.